Guidance, NICE advice and quality standards in development | Guidance

Showing 201 to 210 of 373

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]	Technology appraisal guidance	28 January 2026
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]	Technology appraisal guidance	TBC
Nemolizumab for treating prurigo nodularis [ID6451]	Technology appraisal guidance	TBC
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]	Technology appraisal guidance	TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]	Technology appraisal guidance	28 June 2017
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]	Technology appraisal guidance	TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance	TBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]	Technology appraisal guidance	TBC
Nirogacestat for treating desmoid tumours [ID6453]	Technology appraisal guidance	TBC